Showing Results for: “Glycemic Index and Diabetes”

The New England Journal of Medicine: AMPLITUDE O trial reveals regular use of efpeglenatide has potential to improve outcomes for high-risk diabetes patients with heart or kidney disease Data released today from a large-scale, international clinical trial show significant reduction in the first occurrence of a heart attack, stroke, or death, and a reduction in progression of kidney disease in patients with type 2 diabetes with weekly use of efpeglenatide, an injectable drug with glucose- and weight-lowering effects. The findings were presented at the virtual 81st Scientific Sessions of the

People living with diabetes are invited to share their story of better living made possible due to insulin The American Diabetes Association ® (ADA), along with the nation’s leading diabetes organizations, unveiled Let’s Talk Insulin today, a campaign commemorating the 100th anniversary of the discovery of insulin. Throughout the year, the ADA and other organizations in the diabetes community will showcase a century of advancements and innovations in insulin therapy, as well as what’s ahead through educational events, support resources, and advocacy for research funding. To kick-off the

Leading diabetes researchers and clinicians from around the world highlight impact of pandemic on patient outcomes and key learnings The American Diabetes Association ® (ADA) is kicking off the virtual 81st Scientific Sessions tomorrow and will feature five COVID-19 Symposia, highlighting cutting-edge science and the latest diabetes developments learned during the initial phases of the pandemic. The Symposia will be presented over the course of the annual meeting taking place June 25–29. This latest research comes at a time when individuals with diabetes, and other related underlying health

Novel Weight Loss Drug, Survodutide, Shows Significant Weight Loss of Nearly 19% At 46 Weeks Oral Semaglutide Demonstrates Weight Loss Up to 15% for People with Obesity and Improved Management of Type 2 Diabetes Late breaking data focused on new drug therapy innovations to treat obesity were presented at the American Diabetes Association’s ® (ADA) 83rd Scientific Sessions in San Diego, CA. Two of the studies were also simultaneously published in The Lancet . This comes at a time when more than 37 million Americans live with diabetes, and nearly 90% of people with diabetes are overweight or

Stem Cell-Derived Fully Differentiated Islet Cells Shown to Restore Endogenous Insulin Secretion and Improved Glycemic Control in People Living with Type 1 Diabetes Today, findings from the ongoing clinical trial of VX-880, a phase 1/2, multi-center, single-arm, open-label study in patients with type 1 diabetes (T1D) were presented, demonstrating the potential of stem cell-derived islet cell therapy as a future treatment option for patients with T1D. All patients treated with VX-880 had undetectable insulin secretion and a history of recurrent severe hypoglycemic events (SHE) in the year prior

A federal court has approved a landmark settlement that will ensure children with diabetes in New York City receive the care they need to fully participate in school and school-related activities. This class action settlement resolves claims that New York City, the Department of Education, the Department of Health and Mental Hygiene, and the Office of School Health systemically failed to ensure that students with diabetes could attend school safely and have access to the same educational opportunities as their peers, in violation of the Americans with Disabilities Act (“ADA”), Section 504 of

El Proyecto Tiene Como Objetivo Remover Barreras al Acceso a Cuidados de la Salud para Prevenir la Perdida de Visión El día de hoy, la Asociación Americana de la Diabetes (ADA) y Genentech, miembro del Grupo Roche, anunciaron una nueva colaboración como parte del trabajo en el marco de la iniciativa de la ADA “ Health Equity Now ” para hacer frente a la falta de acceso a exámenes médicos y tratamientos para enfermedades oculares que afectan a las personas con diabetes. La diabetes es la principal causa de pérdida de visión en personas entre 18 y 64 años, y las personas afroamericanas

Primary Care Council will address needs of primary care professionals and advance care for people with diabetes The American Diabetes Association ® (ADA) and six other leading health associations today announced the Primary Care Council, a new collaboration to address the needs of primary care professionals (PCPs) and support diabetes care in the primary care and family practice settings. The Primary Care Council, which includes ADA, American Academy of Family Physicians (AAFP) , American Academy of Physician Associates (AAPA) , American Association of Nurse Practitioners (AANP) , American

A federal court today preliminarily approved a landmark settlement that will ensure children with diabetes in NYC receive the care they need to fully participate in school and school-related activities. This class action settlement resolves claims that New York City, the Department of Education, the Department of Health and Mental Hygiene, and the Office of School Health systemically failed to ensure that students with diabetes could attend school safely and have access to the same educational opportunities as their peers, in violation of the Americans with Disabilities Act (“ADA”), Section

Today, the American Diabetes Association ® (ADA) in collaboration with the American Academy of Ophthalmology , the American Optometric Association, the American Society of Retinal Specialists , and the National Eye Institute , announced a new resource to improve communication between diabetes care clinicians and eye health clinicians. According to the Centers for Disease Control and Prevention (CDC), more than half of all people with diabetes don’t receive an annual dilated and comprehensive eye exam as recommended or are diagnosed with diabetes-related eye problems too late for effective